Page 2 - Michael Olin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials January 12, 2021 GMT MINNEAPOLIS--(BUSINESS WIRE)--Jan 12, 2021-- OX2 Therapeutics, Inc., a privately held Minneapolis company, announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors. “This is a first-of-its kind immunotherapy that works to treat one of the most aggressive and deadly cancers today,” said Christopher Moert...

January 7, 2021 Elizabeth Neil Physicians and scientists at the University of Minnesota have opened a new brain cancer clinical trial and have treated their first patient. This Phase I, first-in-human trial is enrolling patients with a specific type of brain cancer, glioblastoma. The development for this innovative treatment is based on years of research from Michael Olin, PhD, and Christopher Moertel, MD, researchers in the University of Minnesota Medical School’s Division of Hematology and Oncology, Department of Pediatrics, as well as a high-grade canine clinical trial conducte...